SequelSEC

X4 Pharmaceuticals, Inc XFOR

Biological Products, (No Diagnostic Substances) · CIK 0001501697 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$6.50M
Fiscal year ended 2025-12-31
Operating income
-$86.88M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

X4 Pharmaceuticals, Inc (XFOR) reported revenue of $6.50M and net income of -$79.20M for the fiscal year ended 2025-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from X4 Pharmaceuticals, Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

X4 Pharmaceuticals, Inc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue$6.50M$2.60M$0$0$0$3.00M$0$0
Cost of revenue$5.76M$797.00K$0$0UnavailableUnavailableUnavailableUnavailable
Gross profit$743.00K$1.80M$0$0UnavailableUnavailableUnavailableUnavailable
Operating income-$86.88M-$36.40M-$107.52M-$87.57M-$85.11M-$59.87M-$51.70M-$29.08M
Net income-$79.20M-$37.45M-$101.17M-$93.87M-$88.70M-$62.13M-$52.81M-$33.28M
Research & development$72.72M$81.64M$72.02M$61.06M$50.65M$41.93M$30.16M$20.35M
Weighted-average diluted sharesshares 42.29Mshares 6.70Mshares 5.93Mshares 63.53Mshares 25.75Mshares 20.08MUnavailableUnavailable
Pretax income-$79.16M-$37.14M-$101.09M-$93.84M-$88.68M-$61.98M-$52.81M-$33.28M
Income tax expense$41.00K$310.00K$78.00K$28.00K$17.00K$148.00K$0$0
Diluted EPS$-1.87$-5.59$-17.07$-1.52$-3.99$-3.09UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$43.52M$61.52M$35.50M$27.02M$24.70M$20.94M$17.64M$8.74M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

X4 Pharmaceuticals, Inc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Cash & equivalents$217.05M$55.70M$99.22M$121.72M$81.79M$78.71M$126.18M$8.13M
Total assets$290.46M$146.45M$147.26M$155.59M$117.18M$122.87M$160.70M$9.94M
Current assets$261.58M$112.18M$122.08M$128.68M$87.88M$83.31M$129.28M$9.34M
Total liabilities$104.17M$124.30M$96.16M$81.54M$52.76M$50.07M$31.48M$21.62M
Current liabilities$25.76M$32.88M$22.86M$22.32M$14.02M$11.95M$9.45M$7.91M
Total equity incl. NCI$186.29M$22.15M$51.10M$74.05M$64.41M$72.80M$129.22M-$77.09M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$0Unavailable$64.68M
InventoryUnavailable$2.82M$0UnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$573.00K$1.07M$0UnavailableUnavailableUnavailable$0Unavailable
Goodwill$17.35M$17.35M$17.35M$17.35M$17.35M$27.11M$27.11M$0
Long-term debt$75.00M$75.00M$55.00M$32.30M$33.14M$33.18M$20.00M$8.31M
Accounts payable$5.70M$8.62M$8.95M$7.78M$4.28M$3.14M$2.09M$2.97M

Cash flow

X4 Pharmaceuticals, Inc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Operating cash flow-$85.62M-$130.90M-$96.51M-$77.10M-$70.90M-$58.82M-$48.06M-$25.42M
Capital expendituresUnavailable$326.00K$60.00K$103.00KUnavailableUnavailableUnavailableUnavailable
Investing cash flow$8.15M$66.99M-$14.88M-$103.00K-$615.00K-$1.36M$27.23M$0
Financing cash flow$238.63M$20.29M$88.52M$117.23M$74.24M$12.39M$140.66M$6.87M
Net change in cash$161.38M-$43.77M-$22.78M$39.92M$2.41M-$47.38M$119.59M-$18.55M
Stock-based compensation$4.30M$8.20M$8.69M$5.20M$6.18M$5.43M$2.05M$759.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$0$0$2.00M$0$0Unavailable
Depreciation & amortization$1.28M$796.00K$419.00K$513.00K$499.00K$351.00K$103.00K$103.00K

Derived

X4 Pharmaceuticals, Inc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Free cash flowUnavailableUnavailableUnavailable-$77.20MUnavailableUnavailableUnavailableUnavailable
Gross margin11.4%69.3%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-1336.7%-1400.0%UnavailableUnavailableUnavailable-1995.8%UnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue66.1%315.5%UnavailableUnavailableUnavailable180.9%UnavailableUnavailable
Current ratio10.16x3.41x5.34x5.76x6.27x6.97x13.68x1.18x
Revenue YoY growth150.0%UnavailableUnavailableUnavailable-100.0%UnavailableUnavailableUnavailable
Net margin-1218.4%-1440.4%UnavailableUnavailableUnavailable-2071.0%UnavailableUnavailable
R&D / revenue1118.8%3140.1%UnavailableUnavailableUnavailable1397.7%UnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity0.40xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open XFOR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.